LONDON--(BUSINESS WIRE)--Roots Analysis has announced the addition of “HPAPIs and Cytotoxic Drugs Manufacturing Market” report to their portfolio. The report provides an extensive study of the contract manufacturing opportunity for this rapidly expanding market. It identifies various CMOs active in this space, their capabilities with respect to manufacturing of HPAPIs and cytotoxic drugs, scale of operation (laboratory/development/commercial), Occupational Exposure Limits (OELs) and geographic location/spread of the facilities. The focus of this report is primarily to understand the likely future evolution of HPAPIs and cytotoxics over the next decade.
Shefali Asija, the principal analyst, said, “Due to their numerous advantages and increased applications in treatment of cancer and other disorders, HPAPIs and cytotoxics have emerged as one of the key focus areas of researchers and manufacturers across the globe. Despite the fact that production of HPAPIs and cytotoxic drugs requires specialized containment requirements making it a capital extensive business, a lot of CMOs are involved actively in the market.”
The report examines insights gathered from interviews of important stakeholders such as Corden Pharma, Helsinn, Catalent Pharma Solutions and Piramal Healthcare. Asija further stated, “Majority of our work is supported by detailed research. For the purposes of this report, we studied close to 60 investment programs which have taken place since 2004. The success of the market lies in the increasing number of collaborations between contract manufacturers and pharmaceutical companies.” The firm had previously done a focused study on ADC contract manufacturing market; the details of this report can be found at this link.
Key topics covered in the latest report are:
- Analysis of contract manufacturers involved in HPAPIs and cytotoxics manufacturing
- Pharmaceutical companies with in-house manufacturing
- Future market evolution
- Recent deals and partnerships
- Investment programs
- Regulatory landscape
- Special focus on ADC contract manufacturing
- Profiles of leading companies
- Case studies on companies providing ‘one stop shop’ service
Who will benefit from this report?
This research is targeted towards pharma companies and CMOs working in the field of HPAPIs and cytotoxic drugs. In particular, you will benefit if you are an:
- Contract manufacturer
- R&D Manager
- Business Intelligence / Scientific Analyst
- Licensing / Portfolio Manager
- Strategy Manager
or email at email@example.com